New vaccine aims to shield against multiple coronaviruses at once

NCT ID NCT05548439

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental vaccine called VBI-2901a in 103 healthy adults aged 18-64 who had already received at least two doses of a licensed COVID-19 vaccine. The vaccine is designed to protect against three coronaviruses: SARS-CoV-2 (which causes COVID-19), SARS-CoV-1, and MERS-CoV. The main goals were to check safety and see how well the vaccine boosts the immune system's response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Coronavinae infectious disease Coronaviridae infectious disease Orthocoronavirinae infectious disease severe acute respiratory syndrome COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CHU de Québec Université Laval

    Québec, Quebec, G1E 7G9, Canada

  • Canadian Center for Vaccinology

    Halifax, Nova Scotia, B3K 6R8, Canada

  • LMC Manna - Bayview CPU

    Toronto, Ontario, M4G 3E8, Canada

  • LMC Manna Toronto

    Toronto, Ontario, M9W 4L6, Canada

  • Manna Research Inc

    Pointe-Claire, Quebec, H9R 4S3, Canada

  • Ottawa Hospital

    Ottawa, Ontario, K1H 8L6, Canada

  • Red Maple Trials

    Ottawa, Ontario, K1H 1E4, Canada